First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.07 USD 3.56% Market Closed
Updated: Apr 29, 2024

Aquestive Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aquestive Therapeutics Inc
Cash from Operating Activities Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Aquestive Therapeutics Inc
NASDAQ:AQST
Cash from Operating Activities
-$6.4m
CAGR 3-Years
48%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Cash from Operating Activities
$22.8B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
2%
Bristol-Myers Squibb Co
NYSE:BMY
Cash from Operating Activities
$13.9B
CAGR 3-Years
0%
CAGR 5-Years
18%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Cash from Operating Activities
$8.7B
CAGR 3-Years
-15%
CAGR 5-Years
-11%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Cash from Operating Activities
$13B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Cash from Operating Activities
$4.2B
CAGR 3-Years
-13%
CAGR 5-Years
-5%
CAGR 10-Years
-3%

See Also

What is Aquestive Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-6.4m USD

Based on the financial report for Dec 31, 2023, Aquestive Therapeutics Inc's Cash from Operating Activities amounts to -6.4m USD.

What is Aquestive Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
13%

Over the last year, the Cash from Operating Activities growth was 35%. The average annual Cash from Operating Activities growth rates for Aquestive Therapeutics Inc have been 48% over the past three years , 13% over the past five years .